Back to Search
Start Over
Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.
- Source :
-
Frontiers in immunology [Front Immunol] 2023 Sep 06; Vol. 14, pp. 1194912. Date of Electronic Publication: 2023 Sep 06 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Shigellosis (bacillary dysentery) is a severe gastrointestinal infection with a global incidence of 90 million cases annually. Despite the severity of this disease, there is currently no licensed vaccine against shigellosis. Shigella 's primary virulence factor is its type III secretion system (T3SS), which is a specialized nanomachine used to manipulate host cells. A fusion of T3SS injectisome needle tip protein IpaD and translocator protein IpaB, termed DBF, when admixed with the mucosal adjuvant double-mutant labile toxin (dmLT) from enterotoxigenic E. coli was protective using a murine pulmonary model. To facilitate the production of this platform, a recombinant protein that consisted of LTA-1, the active moiety of dmLT, and DBF were genetically fused, resulting in L-DBF, which showed improved protection against Shigella challenge. To extrapolate this protection from mice to humans, we modified the formulation to provide for a multivalent presentation with the addition of an adjuvant approved for use in human vaccines. Here, we show that L-DBF formulated (admix) with a newly developed TLR4 agonist called BECC438 (a detoxified lipid A analog identified as Bacterial Enzymatic Combinatorial Chemistry candidate #438), formulated as an oil-in-water emulsion, has a very high protective efficacy at low antigen doses against lethal Shigella challenge in our mouse model. Optimal protection was observed when this formulation was introduced at a mucosal site (intranasally). When the formulation was then evaluated for the immune response it elicits, protection appeared to correlate with high IFN-γ and IL-17 secretion from mucosal site lymphocytes.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Lu, Das, Howlader, Jain, Hu, Dietz, Zheng, Ratnakaram, Whittier, Varisco, Ernst, Picking and Picking.)
- Subjects :
- Animals
Mice
Female
Enterotoxins immunology
Bacterial Proteins immunology
Bacterial Proteins genetics
Bacterial Toxins immunology
Escherichia coli Proteins immunology
Escherichia coli Proteins genetics
Adjuvants, Immunologic
Disease Models, Animal
Adjuvants, Vaccine
Shigella immunology
Antibodies, Bacterial immunology
Shigella flexneri immunology
Mice, Inbred BALB C
Humans
Toll-Like Receptor 4 agonists
Toll-Like Receptor 4 immunology
Toll-Like Receptor 4 metabolism
Shigella Vaccines immunology
Shigella Vaccines administration & dosage
Dysentery, Bacillary prevention & control
Dysentery, Bacillary immunology
Antigens, Bacterial immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 14
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 37744341
- Full Text :
- https://doi.org/10.3389/fimmu.2023.1194912